In a groundbreaking move, French medtech startup BioSerenity has secured €24 million in funding from Jolt Capital, a prominent private equity firm specializing in growth investments for European deeptech companies. This injection of funds is set to propel BioSerenity’s mission of enhancing personalized patient care through innovative medical services, particularly in the realm of electrophysiology.
About BioSerenity
Founded in 2014 by Pierre-Yves Frouin, BioSerenity is a pioneer in developing medical devices aimed at diagnosing and monitoring patients with chronic diseases such as epilepsy. Initially focused on neurology, the company has expanded its scope to encompass other areas, including sleep disorders and cardiology.
BioSerenity is a frontrunner in the field of neurological diagnostics and sleep disorders, armed with a powerful toolkit that includes medical sensors, smart clothing, a smartphone app, and a web platform. Their secret weapon is Medical AI, used for detecting digital biomarkers. With a strong track record, BioSerenity has more than 300 partners and provides care for an impressive 150,000 patients each year, solidifying its position as a leader in the industry.
Unlocking International Growth
The €24 million investment from Jolt Capital is a strategic move to fuel BioSerenity’s international expansion. The company, already making waves in France and the United States, plans to consolidate its position in these markets while concurrently targeting further growth across Europe. The funding will also be instrumental in deploying advanced AI technologies, empowering healthcare professionals with enhanced diagnostic capabilities. Moreover, BioSerenity aims to fortify its management team, driving continuous innovation and development.
About the Funding
Jolt Capital’s recent investment is a game-changer for BioSerenity’s growth. The funds will speed up global expansion, improve AI for medical diagnoses, and bolster the management team. Jolt Capital’s Managing Partner, Jean Schmitt, stressed the importance of supporting healthcare for French leadership in medicine and industry.
Looking ahead, Vincent Marcel, BioSerenity’s new CEO, is excited about the company’s disruptive technologies. With a focus on growing in Europe and the U.S., Marcel aims to bring personalized, preventive, and cost-effective medicine to more people. The synergy between Jolt Capital’s commitment and BioSerenity’s innovation sets the stage for a bright future.
Conclusion
BioSerenity‘s €24 million funding injection marks a significant milestone in the company’s journey to revolutionize healthcare. The combination of cutting-edge technologies, a commitment to innovation, and strategic investment sets the stage for BioSerenity to continue its mission of providing personalized and advanced medical solutions.
FAQs
How does BioSerenity’s technology contribute to healthcare innovation?
BioSerenity’s technology includes medical sensors, smart clothing, and AI-driven platforms, enabling the diagnosis and monitoring of chronic diseases such as epilepsy, sleep disorders, and cardiology. This integrated approach revolutionizes healthcare by providing personalized and advanced medical solutions.
What is the significance of Jolt Capital’s €24 million investment in BioSerenity?
Jolt Capital’s investment is crucial for BioSerenity’s international expansion, focusing on France, the United States, and Europe. The funds will be used to enhance AI capabilities for medical diagnoses, strengthen the management team, and further develop innovative healthcare solutions.
How does BioSerenity plan to utilize the funding for future growth?
BioSerenity intends to allocate the funding to accelerate international development, deploy more powerful AI technologies for medical diagnoses, and strengthen its management team. The goal is to bring personalized, preventive, and cost-effective medicine for neurological and sleep disorders to a wider patient base.
